论文部分内容阅读
目的探讨普米克令舒联合复方异丙托溴胺雾化吸入治疗小儿毛细支气管炎临床疗效。方法将98例毛细支气管炎患儿随机分成观察组及对照组,每组49例,两组均给予常规对症治疗,观察组加用普米克令舒联合复方异丙托溴胺雾化吸入治疗,疗程均为1周。结果观察组总有效率93.88%,明显优于对照组的73.47%,两组比较具有统计学意义(P<0.01),观察组咳嗽、喘憋、哮鸣音消失时间及住院天数均明显少于对照组,差异有统计学意义(P<0.05)。结论普米克令舒联合复方异丙托溴胺雾化吸入治疗小儿毛细支气管炎疗效显著,安全性高,适合临床推广使用。
Objective To investigate the clinical efficacy of pulmicort respules combined with ipratropium bromide inhalation in the treatment of pediatric bronchiolitis. Methods 98 cases of bronchiolitis were randomly divided into observation group and control group, with 49 cases in each group. Both groups were given conventional symptomatic treatment. The observation group was treated with pulmicort respules combined with ipratropium bromide inhalation, The course of treatment is 1 week. Results The total effective rate in the observation group was 93.88%, which was significantly better than that in the control group (73.47%). The two groups were statistically significant (P <0.01). The cough, wheezing, wheezing disappearance time and hospitalization days in the observation group were significantly less than those in the control group Control group, the difference was statistically significant (P <0.05). Conclusion Pulmicort respules compound ipratropium bromide inhalation therapy for children with bronchiolitis significant effect, high safety, suitable for clinical use.